GlassScriptPhysician profile
Brian C Andrews
NPI 1326127473
$6,613.97
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,184 · 2020: $1,909 · 2021: $1,840 · 2022: $648 · 2023: $33.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $845.58 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $750.53 | 2019-2022 | |
| Amgen INC. | $559.09 | 2019-2022 | |
| Lilly USA, LLC | $552.87 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $545.36 | 2019-2021 | |
| Astellas Pharma US INC | $312.60 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $279.72 | 2019-2021 | |
| Abbvie INC. | $275.15 | 2019-2023 | Vraylar |
| Merck Sharp & Dohme LLC | $265.19 | 2019-2023 | Belsomra, Steglatro, Januvia |
| Abbott Laboratories | $208.71 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $202.19 | 2019-2022 | |
| Glaxosmithkline, LLC. | $197.55 | 2019-2022 | |
| Amarin Pharma, INC. | $181.57 | 2019-2021 | |
| Pfizer INC. | $181.12 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.07 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.